(PGNY) Progyny - Ratings and Ratios

Progyny Inc (NASDAQ:PGNY) is a leading benefits management company specializing in fertility, family building, and womens health solutions. The company offers a comprehensive suite of services designed to optimize treatment outcomes and enhance the overall experience for individuals and families. Progynys solutions include smart cycle treatment bundles, personalized concierge-style support, and access to a network of top-tier fertility specialists. Additionally, Progyny Rx provides integrated pharmacy benefits, ensuring seamless access to necessary medications and care management services. The company also offers an assistance program that covers a range of services such as adoption, surrogacy, doula support, and travel reimbursement for medical care. Progynys approach combines data-driven insights and scientific expertise to deliver high-quality, patient-centered care.

Formerly known as Auxogyn, Inc., Progyny rebranded in 2015 to reflect its expanded focus on comprehensive family-building benefits. Incorporated in 2008 and headquartered in New York, New York, the company has established itself as a key player in the fertility and womens health space. Its services are increasingly being adopted by employers as part of broader employee benefits packages, reflecting the growing recognition of the importance of family-building support in the workplace.

Based on the provided data, here is a 3-month forecast for Progyny Inc:

From a technical perspective, PGNY is showing signs of bullish momentum, with the 20-day moving average (SMA 20) crossing above the 50-day moving average (SMA 50). This indicates potential short-term upside, with support levels likely around $22.00. The average true range (ATR) of 0.82 suggests manageable volatility, making the stock more attractive for risk-averse investors. The last price of $22.84 is trading above the SMA 20 of $22.27, further reinforcing the bullish outlook.

Fundamentally, Progynys forward P/E of 14.20 suggests the market expects strong earnings growth, potentially driven by increasing demand for fertility and family-building benefits. The companys price-to-sales (P/S) ratio of 1.61 indicates a premium valuation, reflecting its strong revenue growth prospects. The return on equity (RoE) of 12.87% highlights efficient use of shareholder capital, which could support further expansion and innovation in its service offerings.